Page 106 - 《中国药房》2021年22期

[17] DECRAMER M，RUTTEN-VAN M M，DEKHUIJZEN P N， [26] DALNEGRO R W，WEDZICHA J A，IVERSEN M，et al.
et al. Effects of N-acetylcysteine on outcomes in chronic Effect of erdosteine on the rate and duration of COPD
obstructive pulmonary disease（bronchitis randomized on exacerbations：the restore study[J]. Eur Respir J，2017，50
NAC cost-utility study，BRONCUS）：a randomised placebo- （4）：700-711.
controlled trial[J]. Lancet，2005，365（9470）：1552-1560. [27] CALVERLEY P M，PAGE C，DAL NEGRO R W，et al.
[18] SCHERMER T，CHAVANNES N，DEKHUIJZEN R，et al. Effect of erdosteine on COPD exacerbations in COPD
Fluticasone and N-acetylcysteine in primary care patients patients with moderate airflow limitation[J]. Int J Chron
with COPD or chronic bronchitis[J]. Respir Med，2009， Obstruct Pulmon Dis，2019，14（2）：2733-2744.
103（4）：542-551. [28] POOLE P，SATHANANTHAN K，FORTESCUE R.
[19] ZHENG J P，WEN F Q，BAI C X，et al. Twice daily Mucolytic agents versus placebo for chronic bronchitis or
N-acetylcysteine 600 mg for exacerbations of chronic chronic obstructive pulmonary disease[J]. Cochrane
obstructive pulmonary disease（PANTHEON）：a randomised， Database Syst Rev，2019，5（5）：D1287.
double-blind placebo-controlled trial[J]. Lancet Respir [29] 陈敏，朱慕云.振动PEP排痰法在慢阻肺患者肺康复中的
Med，2014，2（3）：187-194. 应用研究进展[J].临床肺科杂志，2017，22（7）：1323-
[20] TSE H N，RAITERI L，WONG K Y，et al. Benefits of 1326.
high-dose N-acetylcysteine to exacerbation-prone patients [30] MORETTI M. Pharmacology and clinical efficacy of
with COPD[J]. Chest，2014，146（3）：611-623. erdosteine in chronic obstructive pulmonary disease[J].
[21] PAPI A，ZHENG J，CRINER G J，et al. Impact of smo- Expert Rev Respir Med，2007，1（3）：307-316.
king status and concomitant medications on the effect of [31] MANDRU R，ZHOU C Y，PAULEY R，et al. Conside-
high-dose N-acetylcysteine on chronic obstructive pulmo- rations for and mechanisms of adjunct therapy in
nary disease exacerbations：a post-hoc analysis of the COPD[J]. J Clin Med，2021，10（6）：1225.
PANTHEON study[J]. Respir Med，2019，147：37-43. [32] BARNES P J. Oxidative stress-based therapeutics in COPD
[22] YASUDA H，YAMAYA M，SASAKI T，et al. Carbocis- [J]. Redox Biol，2020，33：101544.
teine reduces frequency of common colds and exacerbations [33] CAZZOLA M，PAGE C，ROGLIANI P，et al. Multifa-
in patients with chronic obstructive pulmonary disease[J]. ceted beneficial effects of erdosteine：more than a mucolytic
J Am Geriatr Soc，2006，54（2）：378-380. agent[J]. Drugs，2020，80（17）：1799-1809.
[23] TATSUMI K，FUKUCHI Y. Carbocisteine improves quality [34] DE FLORA S，BALANSKY R，LA MAESTRA S. Rationale
of life in patients with chronic obstructive pulmonary for the use of N-acetylcysteine in both prevention and ad-
disease[J]. J Am Geriatr Soc，2007，55（11）：1884-1886. juvant therapy of COVID-19[J]. FASEB J，2020，34（10）：
[24] ZHENG J P，KANG J，HUANG S G，et al. Effect of carbo- 13185-13193.
cisteine on acute exacerbation of chronic obstructive pulmo- [35] ROGLIANI P，MATERA M G，PAGE C，et al. Efficacy
nary disease（peace study）：a randomised placebo-con- and safety profile of mucolytic/antioxidant agents in
trolled study[J]. Lancet，2008，371（9629）：2013-2018. chronic obstructive pulmonary disease：a comparative
[25] MORETTI M，BOTTRIGHI P，DALLARI R，et al. The analysis across erdosteine，carbocysteine，and N-acetyl-
effect of long-term treatment with erdosteine on chronic cysteine[J]. Respir Res，2019，20（1）：104.
obstructive pulmonary disease：the equalife study[J]. （收稿日期：2021-06-09 修回日期：2021-09-23）
Drugs Exp Clin Res，2004，30（4）：143-152. （编辑：陈 宏）

《中国药房》杂志——WHO西太平洋地区医学索引（WPRIM）收录期刊，欢迎投稿、订阅

·2784 · China Pharmacy 2021 Vol. 32 No. 22 中国药房 2021年第32卷第22期